Status: Recruiting
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).
Participants needed: 26
Trial details
Phase: Phase 2Age: 6+Biological sex: AllType: InterventionalSponsor: Lexeo TherapeuticsUpdated: Jul 22, 2026Locations: 1
Eligibility criteria
Male or female, age at least 6 years at the time of signing the informed consent... [+5]
Presence of other forms of cardiomyopathy that contribute to heart failure [+6]